Importantly, a series of recent clinical trials have established the effectiveness of sacubitril/valsartan (S/V) in the clinical management of patients with HF [26,27,28] and hypertension [29], further underscoring the therapeutic value of targeting both the NPS and RAAS as sacubitril prevents ANP and BNP degradation via inhibiting neprilysin (NEP) while valsartan blocks ANGII from binding to the AT1 receptor. This evidence concerns the gene AGT and hydrops fetalis.